Snippet from the press release:
Genetics research and a clinical study are today bringing significant news to women experiencing hair loss. A new breakthrough test can now help doctors determine if a woman is likely to benefit from anti-androgen therapies.
Genetic dermatology research and development innovator DermaGenoma, Inc. today announces the HairDX Genetic Test for Female Androgen Sensitivity. The test offers a new genetic screening for women suffering from or at risk of androgenetic alopecia (AGA), and is making its debut to physicians at the International Society of Hair Restoration Surgery’s 18th Annual Scientific Meeting in Boston.
The HairDX Genetic Test for Female Androgen Sensitivity (to be available through dermatologists at a suggested price of $399) examines genetic and epigenetic (genetic control mechanism) variations in a woman’s androgen receptor gene. This analysis will assess her androgen sensitivity to determine if her hair loss has an androgenic origin.
Read the full press release — Breakthrough Genetic Discovery Helps Dermatologists Prescribe Effective Treatment For Female Hair Loss
Women have few options when it comes to treating genetic hair loss, and this new HairDX test seems to point out which women might respond to finasteride and which will not. I heard the announcement at the ISHRS meeting in Boston, but it’s important to note that finasteride is not FDA approved or recommended for treating female hair loss. The drug can pose a serious risk to those women that are pregnant or can become pregnant.
We previously mentioned the HairDX pilot study about finasteride response in women here.